Oricell’s glypican-3 (GPC3)-targeted autologous CAR T, Ori-C101, has moved into a confirmatory registration Phase 2 trial for GPC3-positive advanced hepatocellular carcinoma. The company positions the program as the first CAR T therapy for liver cancer and the first GPC3-directed immune cell therapy to reach this pivotal-stage development step. The milestone upgrades the competitive landscape for cell therapies in HCC, where tumor antigen selection and on-target activity have historically been challenging. It also sets a reference point for how sponsor-driven confirmatory studies may accelerate next steps toward regulatory review.